Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that skin diseases like atopic dermatitis, acne, and psoriasis are associated with increased odds of alcohol use disorder, with psychiatric conditions such as anxiety and depression partially mediating this relationship, accounting for up to 80% of the risk.

This study found that a lipid-based nanoparticle formulation with oleic acid for delivering dutasteride showed lower skin permeation compared to a formulation without oleic acid, indicating its potential for targeted dermal delivery.

In this study, 27.9% of Parkinson's disease patients reported hair loss, with a higher incidence linked to a daily levodopa-equivalent dose over 448 mg, suggesting an association between dopaminergic medication use and hair loss complaints.

This study found that platelet-rich plasma therapy significantly improved hair density and reduced hair shedding in Vietnamese patients with androgenetic alopecia, with high patient satisfaction and minimal side effects.

This review analyzes PDRN's molecular mechanisms and therapeutic applications in anti-aging dermatology but reports no new clinical results, highlighting the need for more standardized protocols and long-term evaluations.

In this study, researchers identified PSENEN mutations that can lead to a form of Dowling-Degos disease, characterized by follicular hyperkeratosis and an increased susceptibility to acne inversa, especially in the presence of certain trigger factors.

PFD patch helps laser tattoo removal, trichoscopy diagnoses AGA, and serum boosts SOD activity.

Farudodstat may help treat alopecia areata by protecting hair follicles.

This review discusses the formation of gintonin LPAs in ginseng during processing and reports no new clinical results; the authors suggest potential benefits against degenerative diseases through LPA receptors.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

This article discusses platelet-rich plasma therapy for cicatricial alopecias like lichen planopilaris and reports no confirmed new clinical results; the authors highlight ongoing uncertainty about its effectiveness and potential risks.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

This study suggests that 3D spheroid cultivation of dermal papilla cells can restore their hair-inductive capabilities, which are lost in 2D-cultured cells.

This study found that using a wearable low-level light therapy device for photodynamic therapy significantly reduced actinic keratosis lesions and improved quality of life in patients with AK of the scalp.

This study explored the creation of 3D-printed baricitinib pills using polylactic acid and found that the doughnut-shaped tablets increased surface area and drug release, with 59% released from the higher concentration pill over 24 hours.

In this study, iL-PRF injections produced significantly better clinical scores for androgenetic alopecia patients compared to controls, especially in those with more severe baseline conditions.

This study found that platelet-rich plasma showed similar efficacy to intralesional triamcinolone acetonide for treating mild patch-type alopecia areata, offering a potential alternative with fewer steroid-related side effects.

This study reports that PDRN, commonly used for wound healing, may also have anti-melanogenesis and potential skin whitening effects in both experimental models and clinical settings.

This commentary discusses platelet-rich plasma for androgenetic alopecia but reports no new research findings.

This study found that the expression of CD117 and platelet-derived growth factor receptor α differs in alopecia areata tissue compared to normal controls, with platelet-derived growth factor receptor α correlating with disease severity.

In this study, researchers found that a PER3 gene SNP may be pathogenic for a new subtype of dyschromatosis universalis hereditaria, especially when combined with a SASH1 mutation.

This expert group provided recommendations for preparing and using platelet-rich plasma in treating androgenetic alopecia, suggesting a manual double-spin method and specific dosing, although further studies on injectable platelet-rich fibrin are needed.

This study suggests that EDA-A2 induces apoptosis in hair follicles by increasing DKK-1 expression, implicating EDA2R signaling as a potential therapeutic target for androgenetic alopecia.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

This study suggests that chronic treatment with TPA in mouse skin selectively expands a keratinocyte subpopulation hyperinducible for ODC, which may be a key target for neoplastic transformation.

This study reported that derivatization with 5-butylpicolinic acid improved the sensitivity for detecting testosterone and DHT in saliva using LC-ESI-MS/MS, with minimal interference from the saliva matrix.

This study found that intravenous administration of a shark-derived receptor antibody, 3P17, promoted hair growth in mice by increasing hair matrix cell proliferation and activating leptin-STAT3 signaling, with transdermal leptin delivery enhancing this effect through improved skin penetration.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

This article is a correspondence that discusses platelet-rich plasma application methods for androgenic alopecia but reports no new clinical results.

This article reviews the potential of PRP as a treatment for spinal pain but calls for established use guidelines and protocols before wider clinical adoption, with no new clinical results reported.